ClinicalTrials.gg
Not yet recruitingNCT07733310Updated Oct 15, 2026

Augmented Depression Therapy (ADepT) Case Series

An interventional study of Augmented Depression Therapy (ADepT) in Depression / Major Depressive Disorder, sponsored by Ohio State University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Ohio State University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 15, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Depression by Ohio State University — 5 open to participants now, 5 under way, none of them phase 3. Depression · Ohio State University.

Planned enrollment
13th of 16
40 · median 120
Started
2027
the only one that year
No phase
14 of 17
3 open now
Registered
16th of 17
by date

Among the 17 studies in Depression by Ohio State University, this one is the 13th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2027, is one of 14 with no phase, and was the 16th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

5 of the 17 studies in Depression by Ohio State University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Depression by Ohio State University, or all of them as a file.
02

Study summary

This research study plans to examine the use of Augmented Depression Therapy (ADepT) in order to evaluate what patients think about ADepT and how well it works. ADepT is a type of therapy that builds wellbeing and is being provided to you as standard of care.

ADepT treatment consists of 15 therapy sessions (typically provided weekly) with each session lasting around 60 minutes. Following these sessions, you can receive five optional booster sessions over the next 12 months with each of these lasting around 60 minutes. Ultimately, the timing and duration of these sessions will be determined between you and your provider and scheduled accordingly.

As part of this study you will be randomized (randomly assigned) to different research assessment lengths before the start of treatment and then will complete assessments for the 12 months following the end of the weekly portion of ADepT treatment. The length of your participation will be between 70 weeks to 82 weeks.

03

Conditions studied

  • Depression / Major Depressive Disorder

Keywords

  • Depression
  • Major Depressive Disorder
  • Major Depressive Episode
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 -65
  2. Currently experiencing a major depressive episode based on the Quick Structured Clinical Interview for Disorders (QuickSCID-5; First \& Williams, 2021)
  3. Scoring > 10 on the PHQ-9
  4. Have sufficient knowledge of written and spoken English to provide consent and utilize therapy resources and take assessment measures throughout the protocol without the assistance of a translator.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of a psychotic or bipolar disorder
  2. History of learning disabilities or organic brain change (e.g., from injury or from neurological disorders)
  3. Active alcohol or substance use disorder or level of use that would interfere with ability to engage in ADepT treatment
  4. Current marked risk to self (self-harm or suicidal ideation) that cannot be managed safely within the ADepT treatment frame
  5. Patients cannot be enrolled while they are currently receiving psychotherapy from a different provider in line with current clinic policy and APA ethical guidelines. The possibility of switching providers/treatments will be addressed following established departmental policies and procedures, transcranial magnetic stimulation, ketamine, esketamine, or electroconvulsive therapy. Patients receiving a stable dose of an antidepressant agent will be considered eligible.
  6. Presence of another psychiatric disorder judged to be primary
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    3 week baseline + ADepT

    Baseline assessments will be made weekly for 3 weeks, followed by a standard course of ADepT.

    Behavioral: Augmented Depression Therapy (ADepT)

  • Experimental
    4 week baseline + ADepT

    Baseline assessments will be made weekly for 4 weeks, followed by a standard course of ADepT.

    Behavioral: Augmented Depression Therapy (ADepT)

  • Experimental
    5 week baseline + ADepT

    Baseline assessments will be made weekly for 5 weeks, followed by a standard course of ADepT.

    Behavioral: Augmented Depression Therapy (ADepT)

  • Experimental
    6 week baseline + ADepT

    Baseline assessments will be made weekly for 6 weeks, followed by a standard course of ADepT.

    Behavioral: Augmented Depression Therapy (ADepT)

  • Experimental
    7 week baseline + ADepT

    Baseline assessments will be made weekly for 7 weeks, followed by a standard course of ADepT.

    Behavioral: Augmented Depression Therapy (ADepT)

  • Experimental
    8 week baseline + ADepT

    Baseline assessments will be made weekly for 8 weeks, followed by a standard course of ADepT.

    Behavioral: Augmented Depression Therapy (ADepT)

Interventions

  • BehavioralAugmented Depression Therapy (ADepT)

    ADepT is a solution-focused behavioral health intervention that blends techniques from cognitive, behavioral, and acceptance-based treatments to help patients manage symptoms of depression and increase wellbeing. It consists of 15 acute treatment sessions and up to 5 booster sessions.

06

What researchers measure

Primary outcomes

  1. Acceptability

    Patient ratings of treatment acceptability

    Time frame: From enrollment to the end of treatment at 82 weeks

  2. Attrition

    Patient attendance records

    Time frame: From enrollment to the end of treatment at 82 weeks.

  3. Adverse Events

    Self-reported adverse events

    Time frame: From enrollment to the end of treatment at 82 weeks.

Secondary outcomes

  1. Montgomery-Asberg Depression Rating Scale (MADRS)

    The MADRS is a clinician-administered, 10-item assessment tool used to measure the severity of depressive symptoms and monitor changes in depression over time. Min=0, Max=60, higher scores indicate worse depression.

    Time frame: From enrollment to the end of treatment at 82 weeks.

  2. Patient Health Questionnaire - 9 Item Version (PHQ-9)

    The PHQ-9 is a 9-item self-report measure of depression severity. Min=0, Max=27, higher scores indicate worse depression.

    Time frame: From enrollment to the end of treatment at 82 weeks.

  3. Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)

    The WEMWBS is a 14-item self-report questionnaire designed to measure positive mental wellbeing, including emotional, psychological, and social functioning. Min=14, Max=70, higher scores indicate higher levels of wellbeing.

    Time frame: From enrollment to the end of treatment at 82 weeks.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Only IRB approved personnel will have access to identifiable data. De-identified data may be shared with other research groups examining similar questions or as a requirement for publication in certain journals.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Aug 2028, 19 months later.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 19 months is close to that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Jan 2027, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Jul 29, 2026
StartEst.
Jan 1, 2027was Aug 2026
Primary completionEst.
Aug 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2026→Jan 1, 2027
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Start date Aug 1, 2026→Jan 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07733310
Responsible party
Jay Fournier (Principal Investigator, Ohio State University) — Principal investigator
First posted
Jul 29, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Aug 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

Jay Fournier, Ph.D.
Contact
Jay.Fournier@osumc.edu
614-814-6485

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion